Kate Haviland, Blueprint Medicines CEO
March 29, 2023 07:17 AM EDT
FDA+

FDA lifts par­tial hold on Blue­print­'s CDK2 in­hibitor

Amber Tong

The FDA has lift­ed a par­tial clin­i­cal hold on Blue­print Med­i­cines’ ear­ly-stage can­cer drug, clear­ing the way for the biotech to dose new pa­tients. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

A service from the Financial Times